Sepsis and multiple organ failure are common causes of death in patients admitted to intensive care units. The incidence of sepsis and associated mortalities has been steadily increasing over the past 20 years. Sepsis is a complex inflammatory condition, the precise causes of which are still poorly understood. Animal models of sepsis have the potential to cause substantial suffering, and many of them have been poorly representative of the human syndrome. However, a number of non-animal approaches, including in vitro, in silico and clinical studies, show promise for addressing this situation. This report is based on discussions held at an expert workshop convened by Focus on Alternatives and held in 2004 at the Wellcome Trust, London. It provides an overview of some non-animal approaches to sepsis research, including their strengths and weaknesses, and argues that they should be prioritised for further development.
PadkinA., GoldfradC., BradyA.R., YoungD., BlackN., & RowanK. (2003). Epidemiology of severe sepsis occurring in the first 24 hours in intensive care units in England, Wales and Northern Ireland. Critical Care Medicine31, 2332–2338.
2.
AngusD.C., Linde-ZwirbleW.T., LidickerJ., ClermontG., CarcilloJ., & PinskyM.R. (2001). Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical Care Medicine29, 1303–1310.
3.
MartinG.S., ManninoD.M., EatonS., & MossM. (2003). The epidemiology of sepsis in the United States from 1979 through 2000. New England Journal of Medicine348, 1546–1554.
4.
SesslerC.N., & ShepherdW. (2002). New concepts in sepsis. Current Opinion in Critical Care8, 465–472.
5.
RiedemannN.C., GuoR.F., & WardP.A. (2003). The enigma of sepsis. Journal of Clinical Investigation112, 460–467.
6.
RedlH., SchlagG., BahramiS., & YaoY.M. (1996). Animal models as the basis of pharmacological intervention in trauma and sepsis patients. World Journal of Surgery20, 487–492.
7.
WardP.A. (2004). The dark side of C5a in sepsis. Nature Reviews: Immunology4, 133–142.
8.
HotchkissR.S., & KarlI.E. (2003). The pathophysiology and treatment of sepsis. New England Journal of Medicine348, 138–150.
9.
RiedemannN.C., GuoR.F., & WardP.A. (2003). Novel strategies for the treatment of sepsis. Nature Medicine9, 517–524.
10.
DeitchE.A. (1998). Animal models of sepsis and shock: a review and lessons learnt. Shock9, 1–11.
11.
Anon. (1986). The Animals (Scientific Procedures) Act 1986.24 pp. London, UK: HMSO.
12.
Anon. (1986). Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. Official Journal of the European Communities358, 1–29.
13.
American College of Chest Physicians (1997). Executive summary. From bench to the bedside: the future of sepsis research. National Institute of Allergy and Infectious Disease and National Heart, Lung and Blood Institute Workshop. Chest111, 744–753.
14.
LewinD.A., & WeinerM.P. (2004). Molecular bio-markers in drug development. Drug Discovery Today9, 976–983.
15.
CalvanoS.E., ThompsonW.A., MarraM.N., CoyleS.M., de RiesthalH.F., TrousdaleR.K., BarieP.S., ScottR.W., MoldawerL.L., & LowryS.F. (1994). Changes in polymorphonuclear leukocyte surface and plasma bactericidal/permeability-increasing protein and plasma lipopolysaccharide-binding protein during endotoxemia or sepsis. Archives of Surgery129, 220–226.
16.
RusswurmS., & ReinhartK. (2004). Procalcitonin mode of action: New pieces in a complex puzzle. Critical Care Medicine32, 1801–1802.
17.
HarbarthS., HoleckovaK., FroidevauxC., PittetD., RicouB., GrauG.E., VadasL., & PuginJ. (2001). Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Geneva Sepsis Network. American Journal of Respiratory and Critical Care Medicine164, 396–402.
18.
De BackerD. (2003). OPS Techniques. Minerva anestesiologica69, 388–391.
19.
De BackerD., CreteurJ., PreiserJ.C., DuboisM.J., & VincentJ.L. (2002). Microvascular blood flow is altered in patients with sepsis. American Journal of Respiratory and Critical Care Medicine166, 1–2.
20.
GiradisM., RinaldiL., BusaniS., FloreI., MauroS., & PasettoA. (2003). Muscle perfusion and oxygen consumption by near-infrared spectroscopy in septic-shock and non-septic-shock patients. Intensive Care Medicine29, 1173–1176.
21.
SairM., EtheringtonP.J., WinloveC., & EvansT.W. (2001). Tissue oxygenation and perfusion in patients with systemic sepsis. Critical Care Medicine29, 1343–1349.
22.
MartinezA., ChioleroR., BollmanM., RevellyJ.P., BergerM., CayeuxC., & TappyL. (2003). Assessment of adipose tissue metabolism by means of subcutaneous microdialysis in patients with sepsis or circulatory failure. Clinical Physiology and Functional Imaging23, 286–292.
23.
TomaselliF., MaierA., & Smolle-JuttnerF.M. (2003). Pharmacokinetics of antibiotics in inflamed and healthy lung tissue. Wiener medizinische Wochenschrift153, 342–344.
24.
CobbJ.P., & O'KeefeG.E. (2004). Injury research in the genomic era. The Lancet363, 2076–2083.
25.
LinM.T., & AlbertsonT.E. (2004). Genomic polymorphisms in sepsis. Critical Care Medicine32, 569–579.
26.
NguyenA., & YaffeM.B. (2003). Proteomics and systems biology approaches to signal transduction in sepsis. Critical Care Medicine31, Suppl. S1–6.
27.
ChenX., & ChristouN.V. (1998). Protective effect of plasma in polymorphonuclear neutrophil-mediated cytotoxicity of endothelial cells in the systemic inflammatory response syndrome. Journal of Leukocyte Biology163, 68–74.
28.
BrownK.A., LewisS.M., HillT.A., MaceyM.G., McCartheyD.A., GrantV.A., & TreacherD.F. (2001). Leucodepletion and the interaction of polymorphonuclear cells with endothelium in systemic inflammatory response syndrome. Perfusion16, Suppl. 75–83.
29.
SendtW., Wolff-VorbeckG., LeipzigerJ., von SpechtB.U., & SchoffelU. (2000). In vitro peritonitis: basic inflammatory reactions in a two-chamber co-culture model of human peritoneum. International Journal of Colorectal Disease15, 229–235.
30.
BoulosM., AstizM.E., BaruaR.S., & OsmanM. (2003). Impaired mitochondrial function induced by serum from septic shock patients is attenuated by inhibition of nitric oxide synthase and poly(ADP-ribose) synthase. Critical Care Medicine31, 352–358.
31.
MoralesC.P., GandiaK.G., RamirezR.D., WrightW.E., ShayJ.W., & SpechlerS.J. (2003). Characterisation of telomerase immortalised normal human oesophageal squamous cells. Gut52, 327–333.
32.
ClermontG., BartelsJ., KumarR., ConstantineG., VodovotzY., & ChowC. (2004). In silico design of clinical trials: a method coming of age. Critical Care Medicine32, 2061–2070.
33.
AnG. (2001). Agent-based computer simulation and SIRS: building a bridge between basic science and clinical trials. Shock16, 266–273.
34.
LamyB., RoyP., CarretG., FlandroisJ.P., & Delignette-MullerM.L. (2002). What is the relevance of obtaining multiple blood samples for culture? A comprehensive model to optimise the strategy for diagnosing bacteremia. Clinical Infectious Diseases35, 842–850.
35.
AnnaneD., OutinH., FischC., & BellissantE. (2004). The effect of waiving consent on enrolment in a sepsis trial. Intensive Care Medicine30, 321–324.
36.
CorwinH.L., GettingerA., PearlR.G., FinkM.P., LevyM.M., ShapiroM.J., CorwinM.J., & ColtonT. (2002). Efficacy of recombinant human erythropoietin in critically ill patients. A randomised controlled trial. EPO Critical Care Trials Group. Journal of the American Medical Association288, 2827–2835.
